| P50 | author | Yiqun Shellman | Q47982789 |
| P2093 | author name string | Yan Lu | |
| | David A Norris | |
| | Mayumi Fujita | |
| | Nabanita Mukherjee | |
| | William A Robinson | |
| | Steven E Robinson | |
| | Chung-Wai Shiau | |
| | Yuchun Luo | |
| | Jung-Chen Su | |
| | Adam Almeida | |
| | Karoline Lambert | |
| P2860 | cites work | Multiplex genome engineering using CRISPR/Cas systems | Q24609428 |
| | Eyes wide open: a critical review of sphere-formation as an assay for stem cells | Q24631827 |
| | A simple technique for quantifying apoptosis in 96-well plates | Q24810168 |
| | CRISPR/Cas9 and cancer targets: future possibilities and present challenges | Q26769907 |
| | Diversity of CRISPR-Cas immune systems and molecular machines | Q26778564 |
| | Targeting the Bcl-2 family for cancer therapy | Q26866936 |
| | Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells | Q28084243 |
| | Identification of a cancer stem cell in human brain tumors | Q28131688 |
| | Development and applications of CRISPR-Cas9 for genome engineering | Q28241526 |
| | Invasive growth: a MET-driven genetic programme for cancer and stem cells | Q28253680 |
| | Identification of selective inhibitors of cancer stem cells by high-throughput screening | Q28255115 |
| | Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells | Q28264780 |
| | Cancer stem cells in solid tumours: accumulating evidence and unresolved questions | Q28293535 |
| | The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53 | Q28476737 |
| | An inhibitor of Bcl-2 family proteins induces regression of solid tumours | Q29547595 |
| | The landscape of somatic copy-number alteration across human cancers | Q29547648 |
| | CRISPR-Cas systems for editing, regulating and targeting genomes | Q29615781 |
| | Genome-scale CRISPR-Cas9 knockout screening in human cells | Q29616044 |
| | In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells | Q29616498 |
| | Intra-tumour heterogeneity: a looking glass for cancer? | Q29620149 |
| | The NOXA-MCL1-BIM axis defines lifespan on extended mitotic arrest | Q30648719 |
| | Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma | Q30890582 |
| | Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy | Q33344524 |
| | Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. | Q33421292 |
| | The therapeutic promise of the cancer stem cell concept | Q33559711 |
| | Autophagy inhibits chemotherapy-induced apoptosis through downregulating Bad and Bim in hepatocellular carcinoma cells | Q33781222 |
| | Cancer stem cells versus phenotype-switching in melanoma | Q34132378 |
| | SOX2 regulates self-renewal and tumorigenicity of human melanoma-initiating cells. | Q34269756 |
| | A CRISPR view of development | Q34342877 |
| | SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma | Q34347235 |
| | Combining targeted drugs to overcome and prevent resistance of solid cancers with some stem-like cell features | Q34619336 |
| | Genomic Classification of Cutaneous Melanoma | Q34670776 |
| | In vivo switching of human melanoma cells between proliferative and invasive states | Q34745037 |
| | BCL-2 family antagonists for cancer therapy | Q34891196 |
| | Improved vectors and genome-wide libraries for CRISPR screening | Q35215629 |
| | Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance? | Q35551802 |
| | Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models. | Q35835794 |
| | Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia | Q35859229 |
| | Small-Molecule and Peptide Inhibitors of the Pro-Survival Protein Mcl-1 | Q35876252 |
| | Inhibition of Mcl-1 promotes senescence in cancer cells: implications for preventing tumor growth and chemotherapy resistance | Q35943976 |
| | ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. | Q36252693 |
| | Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis | Q36288687 |
| | Understanding melanoma stem cells | Q36292299 |
| | ABT-737 synergizes with Bortezomib to kill melanoma cells | Q36425600 |
| | Delving deeper: MCL-1's contributions to normal and cancer biology | Q36494824 |
| | Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma | Q36562077 |
| | Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways. | Q36924443 |
| | Immunotherapy exposes cancer stem cell resistance and a new synthetic lethality | Q37086890 |
| | Mcl-1 is a potential therapeutic target in multiple types of cancer | Q37355825 |
| | Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis | Q37610475 |
| | Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking? | Q37615286 |
| | Mcl-1; the molecular regulation of protein function | Q37764383 |
| | Cancer stem cells: current status and evolving complexities | Q38019174 |
| | Testing the cancer stem cell hypothesis in melanoma: the clinics will tell | Q38052797 |
| | Combining a BCL2 inhibitor with the retinoid derivative fenretinide targets melanoma cells including melanoma initiating cells | Q38944587 |
| | Sphingosine-1-phosphate promotes expansion of cancer stem cells via S1PR3 by a ligand-independent Notch activation | Q38953409 |
| | Oncogenic BRAF signalling increases Mcl-1 expression in cutaneous metastatic melanoma. | Q39080709 |
| | Hedgehog-GLI signaling drives self-renewal and tumorigenicity of human melanoma-initiating cells | Q39325781 |
| | A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation | Q39371671 |
| | Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia | Q39405994 |
| | Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737. | Q39427575 |
| | Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny. | Q39600607 |
| | Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. | Q39860032 |
| | BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. | Q39920726 |
| | Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell | Q40009271 |
| | Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis | Q40018695 |
| | Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer. | Q40134202 |
| | Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis | Q40316401 |
| | RhoC promotes human melanoma invasion in a PI3K/Akt-dependent pathway. | Q40318240 |
| | Myeloid cell factor-1 is a critical survival factor for multiple myeloma | Q40655990 |
| | Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant | Q40990869 |
| | Generation of a human melanocyte cell line by introduction of HPV16 E6 and E7 genes | Q41141757 |
| | Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer | Q42003270 |
| | Endogenous Noxa Determines the Strong Proapoptotic Synergism of the BH3-Mimetic ABT-737 with Chemotherapeutic Agents in Human Melanoma Cells. | Q42100332 |
| | Isolation of human melanoma stem cells using ALDH as a marker | Q42877433 |
| | An ERK-dependent pathway to Noxa expression regulates apoptosis by platinum-based chemotherapeutic drugs. | Q42922881 |
| | Control of mammary stem cell function by steroid hormone signalling. | Q43103606 |
| | Mcl-1 is required for melanoma cell resistance to anoikis | Q43119901 |
| | First MCL-1-selective BH3 mimetics as potential therapeutics for targeted treatment of cancer | Q43166843 |
| | ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays | Q43536416 |
| | Culture and isolation of melanoma-initiating cells. | Q44231584 |
| | Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis | Q44502162 |
| | Downregulation of the antiapoptotic MCL-1 protein and apoptosis in MA-11 breast cancer cells induced by an anti-epidermal growth factor receptor-Pseudomonas exotoxin a immunotoxin | Q45070025 |
| | Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma | Q48044922 |
| | Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia. | Q51685717 |
| | Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy. | Q51746852 |
| | Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. | Q52546411 |
| | Unravelling cancer stem cell potential. | Q53089167 |
| | Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells. | Q53169400 |
| | Beclin 1 restrains tumorigenesis through Mcl-1 destabilization in an autophagy-independent reciprocal manner. | Q53677449 |
| | The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak | Q57279398 |
| | Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells | Q61349793 |
| P433 | issue | 29 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 46801-46817 | |
| P577 | publication date | 2016-04-12 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells | |
| P478 | volume | 8 | |